Free Trial
NASDAQ:AKRO

Akero Therapeutics Q4 2024 Earnings Report

Akero Therapeutics logo
$44.87 -0.44 (-0.97%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$45.38 +0.51 (+1.14%)
As of 05/2/2025 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics EPS Results

Actual EPS
-$0.99
Consensus EPS
-$0.98
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Akero Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Akero Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, February 28, 2025
Conference Call Time
8:30AM ET

Upcoming Earnings

Akero Therapeutics' Q1 2025 earnings is scheduled for Friday, May 9, 2025, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Akero Therapeutics Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Akero Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akero Therapeutics and other key companies, straight to your email.

About Akero Therapeutics

Akero Therapeutics (NASDAQ:AKRO), together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

View Akero Therapeutics Profile

More Earnings Resources from MarketBeat